Dosage ; 10mg OD pc or ac.
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Xarelto | Bayer Schering Pharma | Bayer East Africa Ltd. | 10mg | 10 | Tablet | per tablet | KES 2,720.26 |
| Xarelto | Bayer Schering Pharma | Bayer East Africa Ltd. | 15mg | 14 | Tablet | per tablet | KES 3,810.16 |
| Xarelto | Bayer Schering Pharma | Bayer East Africa Ltd. | 20mg | 14 | Tablet | per tablet | KES 3,810.16 |
| Rivaroxaban More info | |
|---|---|
| Drug Indication | Prevention of venous thromboembolism in adults. |
| Precautions | Concomitant treatment with CYP3A4- and P-gp-inhibitors such as azole-antimycotics and HIV protease inhibitors such as ritonavir; with severe renal impairment; below 18 years of age; product affecting haemostasis such as NSAIDs, platelet aggregation inhibitors and other antithrombotic agents. |
| Contra-Indications | Hypersensitivity to the active substance or excipient(s); active bleeding; any bleeding risk; pregnancy; and lactation. |
| Side Effects | Common: increased GGT; increase in transaminases; anaemia; nausea, post-procedural haemorrhage. Uncommon: increase in: lipase, amylase, blood bilirubin, LDH, alkaline phosphatase, tachycardia, thrombocythaemia, syncope, dizziness, headache, constipation, diarrhoea, abdominal and gastrointestinal pain, dyspepsia, dry mouth, vomiting, renal impairment, pruritus; contusion, pain in extremity, wound secretion, haemorrhage. |
| Dosage | Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery: 10mg OD pc or ac. The first dose should be administered 6-10 hours after surgery when haemostasis has been established. Treatment duration of 5 weeks is recommended for patients undergoing elective hip replacement surgery and 2 weeks for patients undergoing elective knee replacement surgery. |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |